Retrospective claims database cost analysis of second-line sorafenib (SR) or sunitinib (SR) therapy in treatment of patients (pts) with renal cell carcinoma (RCC)

Authors :: S. Meyers
Victoria Barghout
T. B. Dorff
E. Moyneur
DI Quinn
James C. Hu
Source :: Journal of Clinical Oncology. 28:e16521-e16521
Publication Year :: 2010
Publisher :: American Society of Clinical Oncology (ASCO), 2010.
Abstract: e16521 Background: Authors have shown that 1st-year medical costs of SR were less than SU in initial treatment of RCC pts and that baseline comorbidities were similar. Case series data suggest RCC ...

Full Text Access

Tools